血清HBeAg定量变化与慢性乙型肝炎治疗应答的相关性研究

Involvement of dynamic HBeAg quantitation and response during chronic hepatitis B treatment

目的探讨慢性乙型肝炎（CHB）患者抗病毒治疗过程中血清HBeAg定量动态变化对治疗应答的预测价值。方法对接受α-干扰素（α—IFN）治疗的53例患者和核苷类似物（NA）治疗的70例患者，采用电化学发光免疫分析法（ECLIA）测定治疗前、治疗后12、24、48周时血清HBeAg定量，并分析血清HBeAg动态定量与治疗应答相关性。结果干扰素或核苷类似物治疗48周，完全应答者与非完全应答者血清HBeAg基线水平差异无统计学意义（P〉0．05），而治疗12、24周血清HBeAg水平及下降幅度差异有统计学意义（P〈0．05）。治疗24周血清HBeAg定量水平〈100U／ml、下降幅度〉90％的患者完全应答率高（P〈0．05）。结论α-干扰素或核苷类似物治疗慢性乙型肝炎过程中，血清HBeAg定量的动态变化对治疗应答有一定的预测价值。

Objective To observe the changes in quantity of serum HBeAg and the Correlation with response during chronic hepatitis B treatment using interferon-alpha or nucleotside analogue, evaluate the predictive value of dynamic HBeAg quantitation to antiviral response. Methods 53 cases treated with interferon-alpha and 70 cases treated with nucleotide analogue for 48 weeks. Used the Electro chemiluminescence immunoassay（ECLIA）to measure the quantity of the serum HBeAg before treatment and 12 weeks, 24 weeks and 48 weeks after treatment, analysis the correlation of dynamic HBeAg quantitation with antiviral response. Results After 48 weeks treatment, whether interferon-alpha group or nucleotide analogue group, the complete responser quantity of HBeAg before treatment was no significant correlation compared with non-complete responser（ P 〉 0.05）, but at treatment weeks 12 and 24 had correlation with the serum HBeAg level and HBeAg decline degree （ P 〈 0. 05 ） , deferent HBeAg titer and HBeAg quantatition decline degree during treatment achieved deferent complete response rate, HBeAg titer lesser than 100 U/ml and HBeAg quantatition decline degree higher than 90% at treatment weeks 24 achieved more complete response rate After 48 weeks treatment. Conclusion During the treatment CHB with interferon-alpha or nucleotside analogue, the dynamic changes in quantity of serum HBeAg has a relationship with response.